Cannabinoid- and psychedelic-based therapeutics for stress-related disorders
Our research group focuses on developing novel cannabinoid- and psychedelic-based pharmacotherapuetic options for stress-related disorders such as post-traumatic stress disorder and substance use disorders. We also run drug administration studies in healthy, non-clinical populations to gain a better mechanistic understanding of these drugs, particularly as they related to behaviors such as stress reactivity, social processing, and emotion regulation. We use a broad range of research methods, including self-report measures, blood biomarkers, neuroimaging, psychophysiological assessments, and behavioral tests. We work with a multidisciplinary team that includes researchers, physicians, clinicians, therapists, and other healthcare workers. Our goal is to both provide novel pharmacotherapeutic options and an understanding of how they work (and who they may work best for).